Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria

Rheumatology International

Volumn 33, Issue 4, 2013, Pages 973-978

  Bruyere O ^a   Fossi, M ^a   Zegels, B ^a   Leonori, L ^a   Hiligsmann, M ^a   Neuprez, A ^a   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Drug; Economic evaluation; FRAX; Osteoporosis; Reimbursement

Indexed keywords

BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BELGIUM; BONE DENSITY; BONE METABOLISM; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG COST; FAMILY HISTORY; FEMALE; FEMUR NECK; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; GROUPS BY AGE; HIP; HIP FRACTURE; HUMAN; INTERMETHOD COMPARISON; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; OSTEOPOROSIS; OUTCOME ASSESSMENT; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SECONDARY OSTEOPOROSIS; SMOKING; SOCIAL SECURITY; SPINE FRACTURE; VERY ELDERLY; COMPARATIVE STUDY; ECONOMICS; PHYSIOLOGY; RISK FACTOR;

BELGIUM; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIAL SECURITY;

EID: 84886624054     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2460-y     Document Type: Article

References (18)

1. Kanis JA, WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4: 368-381
2. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19: 399-428
3. Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21 (Suppl 2):S407-413
4. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237- 1244
5. Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyere O, Reginster JY (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22(2): 453-461
6. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyere O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64: 612-619
7. Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyere O, Reginster JY (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22: 453-461
8. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62: 105-108
9. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21: 495-505
10. Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A, Kanis JA (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22(3): 955-965
11. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049- 1054
12. McCloskey EV, Johansson H, Oden A, Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 7: 77-83
13. Strom O, Borgstrom F, Kleman M, McCloskey E, Oden A, Johansson H, Kanis JA (2010) FRAX and its applications in health economics-cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47: 430-437
14. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 19: 1395-1408
15. Tosteson AN, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14: 605-615
16. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19: 437-447
17. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21: 381-389
18. Adler RA, Hastings FW, Petkov VI (2010) Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 21: 647-653